Health · Zambia

Zambia and Chinese Firm Plan €190 Million Cholera Vaccine Plant in Lusaka

Zambia and a Chinese company plan to build a cholera vaccine factory worth about €190 million, starting with a $24 million filling and packaging unit near Lusaka. The project aims to cut import dependence and eventually supply other African countries, subject to financing and regulatory approvals.

Zambia and a Chinese company are to build a cholera vaccine factory in a project valued at about 190 million euros, with the aim of reducing the country's reliance on imported vaccines and, over time, supplying other African states.

The first phase is expected to cost $24 million. It involves a unit for filling and packaging oral vaccines in the Lusaka South economic zone. Once fully developed, the site could prepare up to 20 million doses a year. Half of those would be intended for Zambia and the other half for export, subject to the necessary authorisations.

A new company, ZAMVAX, has been created to oversee the whole project. It is 60 per cent owned by the Zambian state-owned group IDC and 40 per cent by the Chinese partner, Jijia. The partners are considering expanding later into paediatric and veterinary vaccines, although the entire plan remains conditional on funding and regulatory approvals.

The project follows Zambia's 2023-2024 cholera epidemic, which recorded more than 20,000 cases and nearly 700 deaths. The outbreak underlined the need to respond quickly to health emergencies.

The plan also sits within a wider continental ambition. After the vaccine shortages seen during the Covid-19 pandemic, the African Union decided that Africa should produce 60 per cent of the vaccines it needs locally by 2040. The continent still depends heavily on imports, making the target a considerable challenge.

The available information does not set out a construction timetable or confirm how the remaining financing will be secured.

More reporting from Voice of Africans